Ionis Pharmaceuticals
| Formerly | Isis Pharmaceuticals, Inc. |
|---|---|
| Company type | Public |
| |
| Industry | Biotechnology |
| Founded | 1989 |
| Founder | Stanley T. Crooke |
| Headquarters | Carlsbad, California, U.S. |
Key people | Brett P. Monia (CEO) Elizabeth L. Hougen (CFO) Joseph Loscalzo (chairman of the board) |
| Products | nusinersen, olezarsen, eplontersen, tofersen, inotersen, volanesorsen |
| Revenue | US$705.1 million (2024) |
| US$453.9 million (2024) | |
| Total assets | US$3.003 billion (2024) |
| Total equity | US$588.4 million (2024) |
Number of employees | 1,069 (2024) |
| Website | ionispharma |
| Footnotes / references | |
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.